Increasing localized access can provide faster results for patients while potentially improving patient outcomes Agreement aims to enable greater access...
Under the terms of the agreement, Acorda will receive an up-front payment of $2.5 million, a near term milestone payment of up to $6 million, $3 million up...
Pancreatic adenocarcinoma (PDAC) is one of the most deadly forms of cancer, in part due to the majority of diagnoses being late-stage; the five-year surviv...
Two newly published pieces indicate that the ophthalmology community is more broadly embracing myopia control and management, according to global cat...
“We are thrilled to have established a partnership with Dr. Reddy’s while toripalimab’s global commercial network has been steadily expan...
A study conducted by the Indian Council of Medical Research (ICMR) in collaboration with the Ministry of Health and Family Welfare, Government of India, wh...
ASC40 is an oral, selective small molecule inhibitor of FASN. Mechanisms of ASC40 for acne are (1) direct inhibition of facial sebum production, through in...
Lupus Awareness Month occurs every May and is an opportunity for lupus-focused organizations to take intentional steps in creating awareness around lupus a...
There is growing recognition that the experimental model systems used in many cancer research projects, which include 2D cell cultures, patient-derived xen...
More than a million years ago, large chunks of the human genome were rearranged—a chance event during egg or sperm formation that led to the deletion...
"We are proud to recognize Pfizer Oncology as the recipient of the 2023 Health Science Award," said Edward M. Messing, MD, FACS, president of the AUA. "Pfi...
Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced U.S. Food and Drug Administration (FDA) approval of its Mini...
The Phase 3 ELEVATE study demonstrated atogepant is effective and well-tolerated for the preventive treatment of episodic migraine in people who previous...
Polivy combination is the first FDA-approved therapy in nearly 20 years for the first-line treatment of diffuse large B-cell lymphoma, an aggressive dise...
© 2025 Biopharma Boardroom. All Rights Reserved.
